On Tuesday, GRAIL received an upgrade to its Relative Strength (RS) Rating, from 63 to 78.
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of over 80 as they launch their biggest climbs. See if GRAIL can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
GRAIL is trying to complete a cup without handle with a 21.47 entry. See if it can break out in heavy volume.
The company posted 0% EPS growth in its most recent report, while sales growth came in at 38%.
The company holds the No. 13 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and Guardian Pharmacy Svcs are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
